{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:00:26Z","timestamp":1782918026924,"version":"3.54.5"},"reference-count":51,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CNS Neurosci Ther"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Limited clinical evidence is available regarding the potential effectiveness of anti\u2010CGRP monoclonal antibodies for the preventive treatment of migraine with aura.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim of the Study<\/jats:title>\n                    <jats:p>This observational study involved a series of migraine patients affected by either migraine with or without aura, who were investigated for any changes in their frequencies and their migraine aura attack characteristics observed during treatment with anti\u2010CGRP Mabs over a 1\u2010year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Twelve migraine patients were included, seven of whom were treated with erenumab, 2 with fremanezumab, and 3 with galcanezumab. Clinical data were collected at baseline, which were defined as 3 months prior to the initiation of treatment, and thereafter at each trimester, over the 1\u2010year treatment period. The parameters included the number of headache and migraine days\/month, the frequency of aura episodes, the number of days with acute drug intakes\/month, and the scores from the migraine disability status scale (MIDAS), and the Headache Impact Test 6 (HIT\u20106).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Anti\u2010CGRP Mbs antibodies induced significant decreases in mean headache and migraine without aura days per month, the number of days with medication intake, as well as MIDAS and HIT\u20106 scores (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). In contrast, the anti\u2010CGRP Mab treatment did not appear to impact the frequency of migraine with aura attacks but seemed to reduce both the intensity and the duration of headache phases of migraine aura. Furthermore, some migraine patients referred to having aura attacks without headache over the course of the treatment period.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the above findings, we hypothesize that anti\u2010CGRP Mabs did not influence neuronal and vascular events related to cortical spreading depression (CSD) which is considered the pathophysiological substrate of aura. Conversely, these antibodies are able to counteract, via their peripheral mechanisms of action, the sensitization of the trigemino\u2010vascular pathway which is triggered by CSD. This aforementioned might explain why in our patients, migraine aura attacks remained unchanged in their frequencies, but the headache phases were either reduced or absent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/cns.14595","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T00:58:11Z","timestamp":1707440291000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of\n                    <scp>anti\u2010CGRP<\/scp>\n                    \u2010targeted therapy on migraine aura: Results of an observational case series study"],"prefix":"10.1111","volume":"30","author":[{"given":"Elena","family":"Cresta","sequence":"first","affiliation":[{"name":"Neurologic Clinic University of Perugia  Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Bellotti","sequence":"additional","affiliation":[{"name":"Neurologic Clinic University of Perugia  Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Neurologic Clinic University of Perugia  Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Corbelli","sequence":"additional","affiliation":[{"name":"Neurologic Clinic University of Perugia  Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-1369","authenticated-orcid":false,"given":"Paola","family":"Sarchielli","sequence":"additional","affiliation":[{"name":"Neurologic Clinic University of Perugia  Perugia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-018-0725-1"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.950"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-014-0453-0"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1001-4"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-020-01037-3"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1231897"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0511-10.2010"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22329"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25731"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13506"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1724285"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynpai.2022.100091"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2016.05.001"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418774299"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2015.03.008"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(94)91234-3"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215435109"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124701"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-6-10"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416678388"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041269"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2020.102097"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2013.09.002"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2018.04.025"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0978-z"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212273"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417735845"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-022-01056-4"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01230-x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77146"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10546-1"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11051228"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4678"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.56.suppl_1.S20"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026119331193"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01466734"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx089"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13341"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420914913"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419896760"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0576-17.2017"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0232-19.2019"},{"issue":"1","key":"e_1_2_8_46_1","first-page":"136","article-title":"CSF levels and binding pattern of novel CGRP receptor antagonists in rhesus monkey and human central nervous system: toward the development of a PET tracer","volume":"29","author":"Sur C","year":"2009","journal-title":"Cephalalgia"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.206458"},{"key":"e_1_2_8_48_1","first-page":"295","article-title":"The CGRP receptor antagonist Olcegepant modulates cortical spreading depression in\u00a0vivo","volume":"37","author":"Eftekhari S","year":"2017","journal-title":"Cephalalgia"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13064"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15585"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cns.14595","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cns.14595","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cns.14595","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:21:53Z","timestamp":1771078913000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cns.14595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/cns.14595"],"URL":"https:\/\/doi.org\/10.1111\/cns.14595","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"2023-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e14595"}}